Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 3/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12327294 | 0.88 | ITGB1 (0.53) | ITGB1ITGA4RAB9AMAPTMEN1 | |
| SCHEMBL14591845 | 0.87 | ITGA4 (0.51) | ITGB1ITGA4RAB9AMAPTMEN1 | |
| SCHEMBL2433435 | 0.87 | RAB9A (0.50) | ITGB1ITGA4RAB9AMAPTMEN1 | |
| SCHEMBL2433025 | 0.86 | ITGB1 (0.46) | ITGB1ITGA4TP53HDAC3HDAC1 | |
| SCHEMBL2440170 | 0.82 | ITGB1 (0.58) | ITGB1ITGA4RAB9AMAPTMEN1 | |
| SCHEMBL91540 | 0.81 | RAB9A (0.55) | RAB9AMAPTMEN1TP53TSHR | |
| SCHEMBL2429653 | 0.78 | AKR1B1 (0.46) | ITGB1ITGA4RAB9AMAPTMEN1 | |
| SCHEMBL2430930 | 0.78 | ITGB1 (0.55) | ITGB1ITGA4MAPTTP53POLB | |
| SCHEMBL12327297 | 0.78 | ITGA4 (0.75) | ITGB1ITGA4 | |
| SCHEMBL12327302 | 0.77 | ITGA4 (0.68) | ITGB1ITGA4CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| CN-100471838-C | VLA-4 inhibitors | DAIICHI SEIYAKU CO (JP) | 2009-03-25 | — | — | CN | disclosed |
| CN-100396680-C | Vla-4 inhibitors | DAICHI PHARMACEUTICAL CO LTD (JP) | 2008-06-25 | — | — | CN | disclosed |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| CN-1699363-A | Vla-4 inhibitors | DAICHI PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| CN-1483024-A | Vla-4 inhibitors | ��һ��������ҩ��ʽ���� | 2004-03-17 | — | — | CN | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ITGB1 5/4885ITGA4 4/4885RAB9A 2530/4885 |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | UGT1A4, VPS4B, CYP3A4 | ITGB1 1987/4885ITGA4 106/4885RAB9A 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.